Private company

EAGLE PHARMACEUTICALS, INC.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. We are committed to developing innovative medicines that result in meaningful improvements in patients’ lives.”66 It is headquartered in Woodcliff Lake, New Jersey.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersWoodcliff Lake, New Jersey1
  • Incorporated inDE2
  • Business address50 Tice Boulevard, Suite 315, Woodcliff Lake, Nj 076772
  • Filer categoryAccelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

25.6%Operating margin3
11.3%Net margin3
84.6%Revenue growth, 20223
15.3%Return on equity3
0.24×Debt to equity3
$50.5MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue27¢$85.5M
  • Research and development11¢$34.1M
  • Selling, general and admin34¢$106.6M
  • Other costs8¢$25.0M
  • Interest1¢$4.0M
  • Income tax8¢$25.8M
  • Profit11¢$35.6M

Out of $316.6M in revenue.3

Where each dollar of operating cash went, fiscal 2022

  • Capital spending0¢$178.0K
  • Share buybacks36¢$18.0M
  • Kept or used elsewhere64¢$32.5M

Out of $50.7M of cash from operations.3

Financial statements

Revenue45673$316.6M in 2022+67% since 2016
0$100.0M$200.0M$300.0M$400.0M2016: $189.5M$189.5M20162017: $236.7M$236.7M2017+25%2018: $213.3M$213.3M2018−10%2019: $195.9M$195.9M2019−8%2020: $187.8M$187.8M2020−4%2021: $171.5M$171.5M2021−9%2022: $316.6M$316.6M2022+85%
Gross profit5$135.0M in 2019−11% since 2018
0$50.0M$100.0M$150.0M$200.0M2018: $151.4M$151.4M20182019: $135.0M$135.0M2019−11%
Operating income45673$81.0M in 2022+52% since 2016
0$25.0M$50.0M$75.0M$100.0M2016: $53.4M$53.4M20162017: $74.0M$74.0M2017+39%2018: $36.6M$36.6M2018−51%2019: $21.8M$21.8M2019−40%2020: $33.0M$33.0M2020+51%2021: $2.8M$2.8M2021−92%2022: $81.0M$81.0M2022+2824%
Net income45673$35.6M in 2022−56% since 2016
-$25.0M0$25.0M$50.0M$75.0M$100.0M2016: $81.5M$81.5M20162017: $51.9M$51.9M2017−36%2018: $31.9M$31.9M2018−39%2019: $14.3M$14.3M2019−55%2020: $12.0M$12.0M2020−16%2021: -$8.6M-$8.6M20212022: $35.6M$35.6M2022
Fiscal year2016201720182019202020212022
Revenue$189.5M4$236.7M5$213.3M6$195.9M7$187.8M3$171.5M3$316.6M3
Cost of revenue$35.8M4$33.7M5$42.4M6$47.9M7$33.6M3$31.5M3$85.5M3
Gross profit$151.4M5$135.0M5
Research and development$28.3M4$32.6M5$44.4M6$36.8M7$30.8M3$51.3M3$34.1M3
Selling, general and admin$53.3M4$71.4M5$60.5M6$76.4M7$78.6M3$75.3M3$106.6M3
Operating expenses$168.8M3$235.7M3
Operating income$53.4M4$74.0M5$36.6M6$21.8M7$33.0M3$2.8M3$81.0M3
Interest$8.0K4$1.1M5$2.7M6$2.7M7$2.6M3$1.6M3$4.0M3
Income before tax-$4.5M3$61.4M3
Income tax-$28.0M4$21.0M5$2.1M6$7.7M7$10.7M3$4.1M3$25.8M3
Net income$81.5M4$51.9M5$31.9M6$14.3M7$12.0M3-$8.6M3$35.6M3
Earnings per share$5.244$3.445$2.166$1.047$0.893-$0.663$2.763
Earnings per share (diluted)$4.964$3.275$2.096$1.017$0.873-$0.663$2.733
Shares (weighted, basic)13.1M shares312.9M shares3
Shares (weighted, diluted)13.1M shares313.1M shares3

Compare EAGLE PHARMACEUTICALS, INC. with another company

Corporate structure

EAGLE PHARMACEUTICALS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of EAGLE PHARMACEUTICALS, INC.

  • J. Goldman & Co LP Filed SCHEDULE 13G on EAGLE PHARMACEUTICALS, INC., latest Aug 14, 2025
  • Nantahala Capital Management, LLC Filed SCHEDULE 13G/A on EAGLE PHARMACEUTICALS, INC., latest Aug 14, 2025 (4 filings since Jul 3, 2024)
  • Nantahala Capital Partners Limited Partnership Filed SCHEDULE 13G on EAGLE PHARMACEUTICALS, INC., latest Feb 19, 2025
  • Union Square Park Capital Management, LLC Filed SCHEDULE 13G/A on EAGLE PHARMACEUTICALS, INC., latest Feb 14, 2025 (3 filings since Oct 8, 2024)
  • BRANDES INVESTMENT PARTNERS, LP Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Nov 14, 2024 (2 filings since Feb 12, 2024)
  • Janus Henderson Group Ltd. Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Nov 14, 2024 (4 filings since Feb 10, 2022)
  • Orin Hirschman Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Oct 9, 2024 (2 filings since Feb 7, 2024)
  • Scott Tarriff Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Mar 18, 2024 (3 filings since Feb 14, 2022)
  • Michael Graves Filed SC 13D on EAGLE PHARMACEUTICALS, INC., latest Feb 14, 2024
  • VANGUARD GROUP INC Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Feb 13, 2024 (3 filings since Feb 9, 2022)
  • State Street Corporation Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Jan 22, 2024 (3 filings since Feb 11, 2022)
  • Park West Asset Management LLC Filed SC 13G/A on EAGLE PHARMACEUTICALS, INC., latest Feb 14, 2022
  • EAGLE PHARMACEUTICALS, INC. Woodcliff Lake, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What EAGLE PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.8M3 Dec 31, 2022$7.6M3 Dec 31, 2021+2.3%
Accumulated depreciation$6.6M3 Dec 31, 2022$6.0M3 Dec 31, 2021+10.8%
Property and equipment, net$1.2M3 Dec 31, 2022$1.6M3 Dec 31, 2021−28.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$55.3M3 Dec 31, 2022$97.7M3 Dec 31, 2021−43.4%
Marketable securities, current$03 Dec 31, 2022$5.3M3 Dec 31, 2021−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$45.0M3 Dec 31, 2022$39.7M3 Dec 31, 2021+13.3%
Intangible assets, net (excluding goodwill)$118.3M3 Dec 31, 2022$10.7M3 Dec 31, 2021+1008.9%
Finite-lived intangibles, gross$134.8M3 Dec 31, 2022$23.9M3 Dec 31, 2021+465.1%
Accumulated amortization$16.5M3 Dec 31, 2022$13.2M3 Dec 31, 2021+24.9%
Finite-lived intangibles, net$118.3M3 Dec 31, 2022$10.7M3 Dec 31, 2021+1008.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$47.8M3 Dec 31, 2022$21.9M3 Dec 31, 2021+118.2%
Raw materials$12.3M3 Dec 31, 2022$7.3M3 Dec 31, 2021+68.8%
Work in process$14.1M3 Dec 31, 2022$9.7M3 Dec 31, 2021+45.5%
Finished goods$21.4M3 Dec 31, 2022$4.9M3 Dec 31, 2021+334.2%

Leadership

Who has led EAGLE PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. David E. Riggs2014–2017
  2. Peter A. Meyers2017–2020
  3. Brian Joseph Cahill2020–2024
  4. Christopher Krawtschuk2024

Chief operating officer

  1. David Pernock2021
201520202025
Board members and other officers (16)

Former names

  • EAGLE PHARMACEUTICALS INCFeb 28, 2007 to Aug 11, 20082

Timeline

  1. Dec 2, 20248-K Entered a material agreement; Change to shareholders' rights35
  2. Nov 27, 20248-K Change of auditor36
  3. Nov 15, 20248-K Listing notice or transfer37
  4. Nov 12, 20248-K Executive or director change; Regulation FD disclosure; Other events38
  5. Oct 31, 20248-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed39
  6. Oct 2, 20248-K Results of operations; Listing notice or transfer; Earlier financial statements no longer reliable40
  7. Aug 27, 20248-K Entered a material agreement; New debt or obligation; Listing notice or transfer41
  8. Aug 5, 20248-K Other events42
  9. Jul 10, 20248-K Entered a material agreement43
  10. May 29, 20248-K Other events44
  11. May 22, 20248-K Listing notice or transfer; Regulation FD disclosure45
  12. May 15, 20248-K Entered a material agreement46

Calendar

When it reported results

  1. Oct 2, 2024Reported quarterly or annual results40
  2. Dec 15, 2023Reported quarterly or annual results47
  3. Nov 9, 2023Reported quarterly or annual results48
  4. Aug 8, 2023Reported quarterly or annual results49
  5. May 9, 2023Reported quarterly or annual results50
  6. Mar 13, 2023Reported quarterly or annual results51
  7. Nov 9, 2022Reported quarterly or annual results52
  8. Nov 7, 2022Reported quarterly or annual results53

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

214 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 89 major events, 48 insider forms, 35 large holders, 32 other. The latest 20:

  1. Aug 14, 2025SCHEDULE 13G EDGAR
  2. Aug 14, 2025SCHEDULE 13G/A EDGAR
  3. Feb 19, 2025SCHEDULE 13G EDGAR
  4. Feb 19, 2025SCHEDULE 13G/A EDGAR
  5. Feb 14, 2025SCHEDULE 13G/A EDGAR
  6. Jan 24, 202515-12G EDGAR
  7. Dec 9, 2024EFFECT EDGAR
  8. Dec 2, 20248-K EDGAR
  9. Nov 27, 2024RW EDGAR
  10. Nov 27, 2024POS AM EDGAR
  11. Nov 27, 2024S-8 POS EDGAR
  12. Nov 27, 2024S-8 POS EDGAR
  13. Nov 27, 2024S-8 POS EDGAR
  14. Nov 27, 2024S-8 POS EDGAR
  15. Nov 27, 2024S-8 POS EDGAR
  16. Nov 27, 2024S-8 POS EDGAR
  17. Nov 27, 20248-K EDGAR
  18. Nov 26, 202425 EDGAR
  19. Nov 19, 20243 EDGAR
  20. Nov 15, 20248-K EDGAR

The 214 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 0 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 2, 2023Tarriff Scott10% ownerSale10,694$13.87$148.3KForm 4
Nov 1, 2023Tarriff Scott10% ownerSale10,925$13.82$151.0KForm 4
Oct 3, 2023Tarriff Scott10% ownerSale10,734$14.46$155.2KForm 4
Oct 2, 2023Tarriff Scott10% ownerSale9,511$15.23$144.9KForm 4
May 16, 2023Tarriff Scott10% ownerSale15,000$19.98$299.7KForm 4
May 15, 2023Tarriff Scott10% ownerSale15,000$21.07$316.0KForm 4
May 12, 2023Tarriff Scott10% ownerSale15,000$20.27$304.0KForm 4
May 11, 2023Tarriff Scott10% ownerSale15,000$20.71$310.6KForm 4
Sep 6, 2022Edlin Richard A.DirectorSale6,800$30.99$210.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How EAGLE PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREAGLE PHARMACEUTICALS, INC.1
  • CIK0000827871
  • Filer statusAccelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ 076771
  • Phone201-326-53001
  • Shares outstanding12,986,971 as of Aug 1, 20239
  • Public float$412.5M as of Jun 30, 20223
  • On EDGAR sinceFeb 28, 20071
  • Filings763 in all: 8-K (250), 4 (225), SC 13G/A (63), 10-Q (28), SC 13G (25), 3 (23), CORRESP (13), 8-K/A (11)1
    All 46 form types

    UPLOAD (10), 10-K (9), DEF 14A (9), DEFA14A (9), SC 13D/A (8), S-8 (6), S-8 POS (6), 144 (5), CT ORDER (5), EFFECT (5), 10-K/A (4), NT 10-Q (4), S-1/A (4), S-3 (3), SC 13D (3), SCHEDULE 13G/A (3), 10-Q/A (2), 4/A (2), 424B5 (2), D (2), DRS/A (2), DRSLTR (2), NT 10-K (2), REGDEX (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 10-QT (1), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), ARS (1), DRS (1), FWP (1), POS AM (1), RW (1), S-1 (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Mar 23, 2023
    Quarterly report (10-Q) Aug 8, 2023
    Proxy statement (DEF 14A) May 1, 2023
    Latest 8-K (8-K) Dec 2, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66